10-Year study checks if HPV test alone can replace pap smear
NCT ID NCT04185389
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows over 1,700 women who previously took part in a cervical cancer screening trial. Researchers want to see if testing for HPV alone is as safe and effective as combining it with a Pap smear over 10 years. Participants provide a cervical sample for both tests, and the study tracks rates of abnormal cell changes. The goal is to improve screening guidelines and reduce unnecessary procedures.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could confirm that HPV testing alone is a safe and effective way to screen for cervical cancer, potentially simplifying screening guidelines.
- What could go wrong
- This is an observational follow-up study, not a new treatment trial. It cannot prove that HPV testing alone prevents cancer better than current methods, and results may not apply to all populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
1,710 people
The number who actually took part.
- Started
-
Sep 2020
- Finished
-
Dec 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Study population consists entirely of participants from a previous RCT.
- Ages
-
30 to 69 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Previous HPV FOCAL study, control arm participants who completed 48 month FOCAL LBC/HPV co-testing with no CIN2+ detected at trial exit * Resident of BC * \<69 years of age (upper age limit for routine screening per BC Cancer Cervix Screening program) * No history of CIN2+ since FOCAL study exit or in the last 5 years * Has not had a hysterectomy * Has never had a diagnosis of invasive cervical cancer
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cervical cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Women's Health Research Institute
Vancouver, British Columbia, V6H3N1, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can pulsed radiation extend life in metastatic cervical cancer?
- Robotic surgery vs standard approaches: does the platform change cancer outcomes?
- New antibody aims to preserve immune checkpoint while fighting cancer
- Smart speculum could bring cervical cancer screening to remote areas
- Your gut bacteria may hold the key to whether immunotherapy works
- Amazon plant put to the test against Cancer's relentless tiredness